Keywords: baycol, launched, third, major, market, bayer, smithkline

Baycol Launched In Third Major Market

Article | 19 February 1998

Print This

Bayer and SmithKline Beecham have launched the HMG-CoA reductaseinhibitor Baycol (cerivastatin) in the USA. It is indicated as an adjunct ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in